DE102008009461A1 - Reducing the wrinkle, comprises applying a cosmetic preparation on the skin to be treated and subsequently working up by means of an ultrasonic applicator - Google Patents
Reducing the wrinkle, comprises applying a cosmetic preparation on the skin to be treated and subsequently working up by means of an ultrasonic applicator Download PDFInfo
- Publication number
- DE102008009461A1 DE102008009461A1 DE102008009461A DE102008009461A DE102008009461A1 DE 102008009461 A1 DE102008009461 A1 DE 102008009461A1 DE 102008009461 A DE102008009461 A DE 102008009461A DE 102008009461 A DE102008009461 A DE 102008009461A DE 102008009461 A1 DE102008009461 A1 DE 102008009461A1
- Authority
- DE
- Germany
- Prior art keywords
- skin
- contact surface
- cosmetic preparation
- derivatives
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 33
- 239000002537 cosmetic Substances 0.000 title claims abstract description 30
- 230000037303 wrinkles Effects 0.000 title abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 23
- 230000037331 wrinkle reduction Effects 0.000 claims abstract description 7
- 238000002604 ultrasonography Methods 0.000 claims description 25
- 238000009499 grossing Methods 0.000 claims description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 7
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 5
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 4
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 claims description 4
- 229930003268 Vitamin C Natural products 0.000 claims description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 4
- 235000019154 vitamin C Nutrition 0.000 claims description 4
- 239000011718 vitamin C Substances 0.000 claims description 4
- 240000009023 Myrrhis odorata Species 0.000 claims description 3
- 235000007265 Myrrhis odorata Nutrition 0.000 claims description 3
- 235000012550 Pimpinella anisum Nutrition 0.000 claims description 3
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 239000003921 oil Substances 0.000 claims description 3
- 235000019198 oils Nutrition 0.000 claims description 3
- 239000000419 plant extract Substances 0.000 claims description 3
- 229940035936 ubiquinone Drugs 0.000 claims description 3
- DBSABEYSGXPBTA-RXSVEWSESA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O DBSABEYSGXPBTA-RXSVEWSESA-N 0.000 claims description 2
- MFYAQFYIDXXKQG-MLCQCVOFSA-N (2s)-2-[[(2s)-4-amino-2-[[(2s)-2-[[(2s)-2-(hexadecanoylamino)-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-4-oxobutanoyl]amino]propanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O MFYAQFYIDXXKQG-MLCQCVOFSA-N 0.000 claims description 2
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 claims description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 2
- 235000019489 Almond oil Nutrition 0.000 claims description 2
- 241000167854 Bourreria succulenta Species 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical compound [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 claims description 2
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 2
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 2
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 2
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims description 2
- 108010075308 N-palmitoyl-seryl-seryl-asparaginyl-alanine Proteins 0.000 claims description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000005642 Oleic acid Substances 0.000 claims description 2
- 108010038807 Oligopeptides Proteins 0.000 claims description 2
- 102000015636 Oligopeptides Human genes 0.000 claims description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- 230000009471 action Effects 0.000 claims description 2
- 239000008168 almond oil Substances 0.000 claims description 2
- 229940061720 alpha hydroxy acid Drugs 0.000 claims description 2
- 150000001280 alpha hydroxy acids Chemical class 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- -1 ascorbyl acetate Chemical compound 0.000 claims description 2
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims description 2
- 229940071097 ascorbyl phosphate Drugs 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 229960005069 calcium Drugs 0.000 claims description 2
- 235000021466 carotenoid Nutrition 0.000 claims description 2
- 150000001747 carotenoids Chemical class 0.000 claims description 2
- 235000019693 cherries Nutrition 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- 229940108925 copper gluconate Drugs 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 150000002170 ethers Chemical class 0.000 claims description 2
- 235000008524 evening primrose extract Nutrition 0.000 claims description 2
- 229940089020 evening primrose oil Drugs 0.000 claims description 2
- 239000010475 evening primrose oil Substances 0.000 claims description 2
- 229930003935 flavonoid Natural products 0.000 claims description 2
- 150000002215 flavonoids Chemical class 0.000 claims description 2
- 235000017173 flavonoids Nutrition 0.000 claims description 2
- 229940020356 folic acid and derivative as antianemic Drugs 0.000 claims description 2
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 claims description 2
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 claims description 2
- 235000020664 gamma-linolenic acid Nutrition 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- 229960002733 gamolenic acid Drugs 0.000 claims description 2
- 229940002508 ginger extract Drugs 0.000 claims description 2
- 235000020708 ginger extract Nutrition 0.000 claims description 2
- 239000008169 grapeseed oil Substances 0.000 claims description 2
- 238000010348 incorporation Methods 0.000 claims description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 229930013686 lignan Natural products 0.000 claims description 2
- 235000009408 lignans Nutrition 0.000 claims description 2
- 150000005692 lignans Chemical class 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 claims description 2
- 235000019136 lipoic acid Nutrition 0.000 claims description 2
- 235000012661 lycopene Nutrition 0.000 claims description 2
- 229960004999 lycopene Drugs 0.000 claims description 2
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims description 2
- 239000001751 lycopene Substances 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229960001983 magnesium aspartate Drugs 0.000 claims description 2
- RXMQCXCANMAVIO-CEOVSRFSSA-L magnesium;(2s)-2-amino-4-hydroxy-4-oxobutanoate Chemical compound [H+].[H+].[Mg+2].[O-]C(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC([O-])=O RXMQCXCANMAVIO-CEOVSRFSSA-L 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 229960003966 nicotinamide Drugs 0.000 claims description 2
- 235000005152 nicotinamide Nutrition 0.000 claims description 2
- 239000011570 nicotinamide Substances 0.000 claims description 2
- 239000002777 nucleoside Substances 0.000 claims description 2
- 125000003835 nucleoside group Chemical group 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 2
- 235000021313 oleic acid Nutrition 0.000 claims description 2
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 2
- 235000013824 polyphenols Nutrition 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 229940108325 retinyl palmitate Drugs 0.000 claims description 2
- 235000019172 retinyl palmitate Nutrition 0.000 claims description 2
- 239000011769 retinyl palmitate Substances 0.000 claims description 2
- 229960004889 salicylic acid Drugs 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 2
- 235000021286 stilbenes Nutrition 0.000 claims description 2
- 150000001629 stilbenes Chemical class 0.000 claims description 2
- 235000000346 sugar Nutrition 0.000 claims description 2
- 150000008163 sugars Chemical class 0.000 claims description 2
- 229960002663 thioctic acid Drugs 0.000 claims description 2
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims description 2
- 229940040064 ubiquinol Drugs 0.000 claims description 2
- QNTNKSLOFHEFPK-UPTCCGCDSA-N ubiquinol-10 Chemical compound COC1=C(O)C(C)=C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=C1OC QNTNKSLOFHEFPK-UPTCCGCDSA-N 0.000 claims description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 2
- 229940096998 ursolic acid Drugs 0.000 claims description 2
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- 239000011701 zinc Substances 0.000 claims description 2
- 150000005206 1,2-dihydroxybenzenes Chemical class 0.000 claims 1
- 239000007764 o/w emulsion Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 8
- 230000008569 process Effects 0.000 abstract description 3
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 230000010355 oscillation Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 22
- 206010040954 Skin wrinkling Diseases 0.000 description 9
- 230000032683 aging Effects 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000001217 buttock Anatomy 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001746 injection moulding Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- BUHVIAUBTBOHAG-FOYDDCNASA-N (2r,3r,4s,5r)-2-[6-[[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl]amino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound COC1=CC(OC)=CC(C(CNC=2C=3N=CN(C=3N=CN=2)[C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)C=2C(=CC=CC=2)C)=C1 BUHVIAUBTBOHAG-FOYDDCNASA-N 0.000 description 1
- TYYHDKOVFSVWON-UHFFFAOYSA-N 2-butyl-2-methoxy-1,3-diphenylpropane-1,3-dione Chemical compound C=1C=CC=CC=1C(=O)C(OC)(CCCC)C(=O)C1=CC=CC=C1 TYYHDKOVFSVWON-UHFFFAOYSA-N 0.000 description 1
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 1
- BNMGUJRJUUDLHW-HCZMHFOYSA-N Madecassoside Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(C[C@@H](O)[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O BNMGUJRJUUDLHW-HCZMHFOYSA-N 0.000 description 1
- BNMGUJRJUUDLHW-HLUHVYOBSA-N Madecassoside Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5[C@H](O)C[C@@]34C)[C@@H]2[C@H]1C)C(=O)O[C@@H]6O[C@H](CO[C@@H]7O[C@H](CO)[C@@H](O[C@@H]8O[C@H](C)[C@H](O)[C@@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@@H](O)[C@H](O)[C@H]6O BNMGUJRJUUDLHW-HLUHVYOBSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940099583 aluminum starch octenylsuccinate Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 description 1
- 229960005193 avobenzone Drugs 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- DLAHAXOYRFRPFQ-UHFFFAOYSA-N dodecyl benzoate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC=CC=C1 DLAHAXOYRFRPFQ-UHFFFAOYSA-N 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 229940100524 ethylhexylglycerin Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000004872 foam stabilizing agent Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 229940090813 madecassoside Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- FMJSMJQBSVNSBF-UHFFFAOYSA-N octocrylene Chemical group C=1C=CC=CC=1C(=C(C#N)C(=O)OCC(CC)CCCC)C1=CC=CC=C1 FMJSMJQBSVNSBF-UHFFFAOYSA-N 0.000 description 1
- 229960000601 octocrylene Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000002602 strong irritant Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000029305 taxis Effects 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- IAQRGUVFOMOMEM-ONEGZZNKSA-N trans-but-2-ene Chemical compound C\C=C\C IAQRGUVFOMOMEM-ONEGZZNKSA-N 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000004506 ultrasonic cleaning Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0092—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin using ultrasonic, sonic or infrasonic vibrations, e.g. phonophoresis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A45—HAND OR TRAVELLING ARTICLES
- A45D—HAIRDRESSING OR SHAVING EQUIPMENT; EQUIPMENT FOR COSMETICS OR COSMETIC TREATMENTS, e.g. FOR MANICURING OR PEDICURING
- A45D2200/00—Details not otherwise provided for in A45D
- A45D2200/25—Kits
-
- A—HUMAN NECESSITIES
- A45—HAND OR TRAVELLING ARTICLES
- A45D—HAIRDRESSING OR SHAVING EQUIPMENT; EQUIPMENT FOR COSMETICS OR COSMETIC TREATMENTS, e.g. FOR MANICURING OR PEDICURING
- A45D44/00—Other cosmetic or toiletry articles, e.g. for hairdressers' rooms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/10—Characteristics of apparatus not provided for in the preceding codes with further special therapeutic means, e.g. electrotherapy, magneto therapy or radiation therapy, chromo therapy, infrared or ultraviolet therapy
- A61H2201/105—Characteristics of apparatus not provided for in the preceding codes with further special therapeutic means, e.g. electrotherapy, magneto therapy or radiation therapy, chromo therapy, infrared or ultraviolet therapy with means for delivering media, e.g. drugs or cosmetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H23/00—Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms
- A61H23/02—Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms with electric or magnetic drive
- A61H23/0245—Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms with electric or magnetic drive with ultrasonic transducers, e.g. piezoelectric
Abstract
Description
Die Erfindung betrifft ein Verfahren zur Reduktion der Zeichen der Hautalterung, insbesondere zur Milderung und Prävention von Falten und Mimikfältchen und der Hautglättung und Verbesserung der Oberflächenstruktur, dadurch gekennzeichnet, dass eine kosmetische Zubereitung auf die zu behandelnde Haut appliziert wird und anschließend mit Hilfe eines Ultraschallapplikators in die zu glättende Haut eingearbeitet wird oder dass eine kosmetische Zubereitung einen Ultraschallapplikator aufgetragen wird, der Ultraschallapplikator in Gang gesetzt wird und die zu behandelnde Haut anschließend mit Hilfe des Ultraschallapplikators mit Ultraschall behandelt wird, wobei die kosmetische Zubereitung in beiden Verfahrenswegen mindestens Haut glättenden Wirkstoff enthält.The The invention relates to a method for reducing signs of aging of the skin, in particular for the alleviation and prevention of wrinkles and Mimic wrinkles and skin smoothing and improvement the surface structure, characterized in that a cosmetic preparation is applied to the skin to be treated and then with the help of an ultrasound applicator is incorporated into the skin to be smoothed or that one cosmetic preparation applied an ultrasonic applicator the ultrasound applicator is started and that too then treated skin using the ultrasound applicator is treated with ultrasound, the cosmetic preparation at least skin-smoothing agent in both methods contains.
Kosmetische Zubereitungen, die nach Applikation auf die Haut eine Glättung der Haut (Faltenreduktion) hervorrufen sollen, gibt es viele. Insbesondere ist es im Stand der Technik weit verbreitet, kosmetische Zubereitungen mit sogenannten Haut glättenden Wirkstoffen anzureichern, da diese eine Reduktion der Faltentiefe versprechen.cosmetic Preparations which, after application to the skin, have a smoothing effect of the skin (wrinkle reduction), there are many. Especially It is widely used in the art, cosmetic preparations to enrich with so-called skin smoothing agents, as these promise a reduction in wrinkle depth.
Die Falten reduzierende Leistung der Zubereitungen bei einmaliger Applikation reicht aber bei faltiger Haut nicht aus, um eine merkliche und anhaltende Faltenreduktion über einen längeren Zeitraum zu erhalten. Nur ein wiederholtes Applizieren schafft hierbei Linderung.The Wrinkle reducing performance of the preparations with a single application but is not enough in wrinkled skin to a noticeable and persistent Wrinkle reduction over a longer period too receive. Only repeated application creates relief.
Als Ultraschall bezeichnet man Schallwellen oberhalb der menschlichen Hörschwelle, mit Frequenzen zwischen 20 kHz und 1 GHz. Der Übergang dieser Schallwellen vom Ultraschallerreger in Festkörper oder Flüssigkeiten erfolgt nur, wenn die Schallwellen in unmittelbarer Nähe abgestrahlt werden oder ein Koppelmedium angepasster akustischer Eigenschaften sowie bestimmter Dicke dazwischen ist.When Ultrasound refers to sound waves above the human Hearing threshold, with frequencies between 20 kHz and 1 GHz. The transition of these sound waves from the ultrasound exciter in solids or liquids only happens when the sound waves radiated in close proximity or a coupling medium adapted acoustic properties as well as certain thickness in between.
In Flüssigkeiten breitet sich Ultraschall bis zu einer bestimmten Intensität dämpfungsarm aus. Ab einem Grenzwert kommt es jedoch zur Bildung von Dampfblasen (Kavitation), welche bei ihrem Zusammenfallen extrem hohe Drücke und Temperaturen hervorrufen können. Dieser Effekt wird zum Beispiel zur Ultraschallreinigung ausgenutzt.In Liquids spreads ultrasound to a certain extent Intensity low attenuation. From a limit However, it comes to the formation of vapor bubbles (cavitation), which when they collapse, extremely high pressures and temperatures can cause. This effect is for example for Ultrasonic cleaning exploited.
Zur Erzeugung von Ultraschall eignen sich dynamische und elektrostatische Lautsprecher sowie insbesondere Piezolautsprecher, d. h. membrangekoppelte Platten aus piezoelektrischer Keramik, welche durch Umkehr des Piezo-Effekts zu Schwingungen angeregt werden. Mittels piezoelektrischer Kunststoffe (PVDF) lassen sich auch direkt Membranen ansteuern, was ein verbessertes Übertragungsverhalten hervorruft.to Generation of ultrasound are dynamic and electrostatic Loudspeakers and in particular piezo loudspeakers, d. H. membrane-coupled Pieces of piezoelectric ceramic, which by reversing the piezo effect be excited to vibrate. By means of piezoelectric plastics (PVDF) can also be controlled directly membranes, resulting in an improved transmission behavior causes.
Die Verwendung von Ultraschall für bildgebende Verfahren ist seit langem bekannt. Hierbei wird Ultraschall mit einer Frequenz von 1 bis 40 MHz und niedriger Intensität, in der Regel um 100 mW/cm2, in den Körper eingestrahlt und die Reflexion der Schallewellen gemessen. Auf Grund der unterschiedlichen Gewebedichten, lässt sich aus dem Reflexionsmuster eine Bild ableiten. Dieses Verfahren wird als Sonografie bezeichnet. Ultraschall höherer Energie wird zur Ultraschalltherapie angewandt, welches eine Beschleunigung von Selbstheilungsprozessen hervorruft, denn mittels des eingeleiteten Ultraschalls kann gezielt Wärme im inneren des Körpers erzeugt werden.The use of ultrasound for imaging has been known for a long time. Here, ultrasound with a frequency of 1 to 40 MHz and low intensity, usually by 100 mW / cm 2 , irradiated into the body and measured the reflection of the sound waves. Due to the different densities of the fabric, an image can be derived from the reflection pattern. This procedure is called sonography. Ultrasound of higher energy is used for ultrasound therapy, which causes an acceleration of self-healing processes, because by means of the introduced ultrasound can be specifically generated heat inside the body.
Aus
der
Für den Fachmann unerwartet war, dass unter Verwendung eines Ultraschallapplikators, der eine Ultraschalquelle aufweist, welche eine Frequenz von unter 3 MHZ ausstrahlt, die Einarbeitung von kosmetischen Zubereitungen, die den Zeichen der Hautalterung entgegen wirken, eine erheblich stärkere Wirkung gegen die Zeichen der Hautalterung hervorrufen, ohne das die Wirkstoffe zerstört werden und besser als wenn sie normal mit den Fingern/Händen eingearbeitet wird.For the skilled artisan was unexpected in that using an ultrasonic applicator, having an ultrasonic source having a frequency of below 3 MHZ, the incorporation of cosmetic preparations, which counteract the signs of aging, a considerable produce stronger effects against signs of aging, without which the active ingredients are destroyed and better than if it is worked in normally with the fingers / hands.
Unter der ,Wirkung gegen die Zeichen der Hautalterung' werden vom Fachmann insbesondere die Milderung und Prävention von Falten und Mimikfältchen und die Hautglättung und Verbesserung der Oberflächenstruktur bzw. Hautglättung subsumiert.Under the 'action against the signs of aging' are made by the expert in particular the mitigation and prevention of wrinkles and Mimic wrinkles and skin smoothing and improvement subsumes the surface structure or skin smoothing.
Insbesondere sind Zubereitungen vorteilhaft, die mindestens einen Haut glättenden Wirkstoff aus der Gruppe Pflanzenextrakte, insbesondere Kirschblütenextrakt, Ingwerextrakt, Anisextrakt, Niacinamid, Vitamin C und dessen Derivate, Vitamin E und dessen Derivate, Ubiquinon (insbesondere Q10), Ubiquinol, Retinylpalmitat, Ursolsäure, natürliche Öle, insbesondere Traubenkernöl, Nachtkerzenöl, Mandelöl, Palmitoyloligopeptide, Palmitoyl tetra peptid, Magnesium aspartat, Zink, Kupfergluconat, Madecassoside, Natriumhyaluronat, Salicylsäure, Calcium, Carotinoide (insbesondere Lycopin) und deren Derivate, Liponsäure und deren Derivate, α-Hydroxysäuren (insbesondere Citronensäure, Milchsäure, Apfelsäure), ungesättigte Fettsäuren und deren Derivate (insbesondere γ-Linolensäure, Linolsäure, Ölsäure), Folsäure und deren Derivate, Flavonoide, Polyphenole, Catechine, Vitamin C und Derivate (insbesondere Ascorbylpalmitat, Mg-Ascorbylphosphat, Ascorbylacetat), Lignane, Stilbene enthalten. Ebeso sind Zubereitungen die Derivate, insbesondere Salze, Ester, Ether, Zucker, Nukleotide, Nukleoside, Peptide und Lipide, der zuvor genannten Wirkstoffe enthalten erfindungsgemäß.In particular, preparations are advantageous, the at least one skin-smoothing active ingredient from the group of plant extracts, especially cherry blossom extract, ginger extract, anise extract, niacinamide, vitamin C and its derivatives, vitamin E and its derivatives, ubiquinone (especially Q10), ubiquinol, retinyl palmitate, ursolic acid, natural oils, especially grapeseed oil, evening primrose oil, almond oil, palmitoyl oligopeptides, palmitoyl tetrapeptide, magnesium aspartate, zinc, copper gluconate, madecassoside, sodium hyaluronate, Salicylic acid, calcium, carotenoids (especially lycopene) and their derivatives, lipoic acid and derivatives thereof, α-hydroxy acids (especially citric acid, lactic acid, malic acid), unsaturated fatty acids and their derivatives (in particular γ-linolenic acid, linoleic acid, oleic acid), folic acid and derivatives thereof , Flavonoids, polyphenols, catechins, vitamin C and derivatives (especially ascorbyl palmitate, Mg ascorbyl phosphate, ascorbyl acetate), lignans, stilbenes. Ebeso are preparations, the derivatives, in particular salts, esters, ethers, sugars, nucleotides, nucleosides, peptides and lipids, the aforementioned active substances contain according to the invention.
Zubereitungen im Sinne der Erfindung sind insbesondere Emulsionen, die neben einer Wasserphase auch eine Ölphase enthalten. Der Vorteil von Emulsionen ist, dass die Gleiteigenschaften erheblich besser sind als bei rein wässrigen Zubereitungen. Die Haut wird dadurch viel weniger gereizt (irritiert) als bei der bekannten Reinigungs- bzw. Mikroabrassionsbehandlung. Die mit dem erfindungsgemäßen Verfahren erzielten Ergebnisse sind bei genauerer Betrachtung nicht vergleichbar obwohl die augenscheinliche Betrachtung der behandelten Hautareale nicht unbedingt einen Unterschied zeigt. Das erfindungsgemäße Verfahren wirkt sich durch seine verstärkte Faltenreduktion auf die tiefer liegenden Hausschichten (Bindegewebe) aus und nicht wie der Stand der Technik auf die oberste tote Zellschicht. Dar erfindungsgemäße Verfahren zeigt dadurch eine länger andauernde Wirkung die sich bei regelmäßiger Anwendung in einer allgemeinen Verjüngung der Haut widerspiegelt. Eine regelmäßige Mikrodermabrasionsbehandlung ist auf Grund der starken Reizwirkung dagegen nicht durchführbar und würde zu einer anhaltenden Schädigung führen, da mit dem Entfernen der toten Hautzellen eine hauteigene Schutzwirkung verloren ginge.preparations For the purposes of the invention are in particular emulsions, in addition to a Water phase also contain an oil phase. The advantage of Emulsions is that the sliding properties are significantly better than in purely aqueous preparations. The skin is thereby much less irritated (irritated) than in the known cleaning or microabrasion treatment. The with the inventive Method results are not on closer inspection comparable though the apparent consideration of the treated Skin areas do not necessarily show a difference. The invention Procedure affects by its increased wrinkle reduction on the lower lying house layers (connective tissue) and not like the state of the art on the top dead cell layer. Dar inventive Process thus shows a longer-lasting effect which, with regular use in a general Rejuvenation of the skin reflects. A regular Microdermabrasion treatment is due to the strong irritant effect not feasible and would become one cause prolonged damage, as with removal the dead skin cells would have lost their own protective effect.
Die Zubereitungen enthalten gemäß der Erfindung außer den vorgenannten Substanzen gegebenenfalls die in der Kosmetik üblichen Zusatzstoffe, beispielsweise Parfüm, Farbstoffe, antimikrobielle Stoffe, rückfettende Agentien, Komplexierungs- und Sequestrierungsagentien, Perlglanzagentien, Pflanzenextrakte, Vitamine, Wirkstoffe, Konservierungsmittel, Bakterizide, Pigmente, die eine färbende Wirkung haben, Verdickungsmittel, weichmachende, anfeuchtende und/oder feucht haltende Substanzen, oder andere übliche Bestandteile einer kosmetischen oder dermatologischen Formulierung wie Alkohole, Polyole, Polymere, Schaumstabilisatoren, Elektrolyte, organische Lösemittel oder Silikonderivate.The Preparations contain according to the invention except the above-mentioned substances optionally the usual in cosmetics Additives, for example perfume, dyes, antimicrobial Substances, moisturizing agents, complexing and sequestering agents, Pearlescent agents, plant extracts, vitamins, active ingredients, preservatives, Bactericides, pigments that have a coloring effect, Thickener, softening, moisturizing and / or moisturizing Substances, or other common ingredients of a cosmetic or dermatological formulation such as alcohols, polyols, polymers, Foam stabilizers, electrolytes, organic solvents or silicone derivatives.
Erfindungsgemäß weisen die Ultraschallapplikatoren eine Ultraschallquelle auf, die eine plane oder leicht gewölbte Auflagefläche (Kontaktfläche) aufweisen, die vom Ulltraschallerreger in Schwingung versetzt wird und den Kontrakt zur Applikationsfläche auf dem Körper herstellt. Beim erfindungsgemäßen Verfahren wird die Auflagefläche (Kontaktfläche) mit der kosmetischen Zubereitung benetzt und diese anschließend unter Ultraschallerregung auf der Haut appliziert oder die kosmetische Zubereitung wird aus die Haut aufgebracht und anschließend mit der ultraschallerregten Auflagefläche in die Haut eingearbeitet.According to the invention The ultrasonic applicators on an ultrasonic source, the one flat or slightly curved support surface (contact surface) have, which is vibrated by the Ulltraschallerreger and the contract with the application area on the body manufactures. In the method according to the invention is the bearing surface (contact surface) with the cosmetic Wets the preparation and then under ultrasound excitation applied on the skin or the cosmetic preparation is made the skin applied and then with the ultrasound-excited Support surface incorporated into the skin.
Der Ultraschallapplikator weist einen Ultraschallerreger auf, der z. B. durch eine Batterie oder Akkumulator gespeist wird. Es ist auch im Sinne der Erfindung alternative stromlose Antriebseinheiten zu verwenden, z. B. Federantriebe oder Federaufzüge. Im Sinne der Erfindung ist es als Ultraschallerzeuger piezoelektrische Quarz- oder Keramikschwinger zu verwenden, an welche eine Wechselspannung mit deren Eigenresonanzfrequenz (oder einer Oberschwingung davon) angelegt wird. Die Oberfläche des Ultraschallerzeugers selbst kann dabei die Kontaktfläche ausbilden oder die vom Ultraschallerzeuger generierten Schwingungen werden über ein Koppelmedium auf die Kontaktfläche des Applikators übertragen. Es ist von Vorteil, wenn die Oberfläche der Kontaktfläche glatt ist, insbesondere poliert, eloxiert oder verchromt ist. Raue oder strukturierte Oberflächen wirken abbrasiv, haben also einen Peelingeffekt, welcher bei besonderen Ausführungsformen gewünscht sein kann.Of the Ultrasonic applicator has an ultrasonic exciter, the z. B. is powered by a battery or accumulator. It is also in the context of the invention, alternative electroless drive units to use, for. B. spring drives or spring lifts. For the purpose of According to the invention, as an ultrasonic generator, it is piezoelectric quartz or ceramic oscillator, to which an AC voltage with their natural resonance frequency (or a harmonic thereof) is created. The surface of the ultrasound generator itself can form the contact surface or the ultrasonic generator generated vibrations are on a coupling medium transfer the contact surface of the applicator. It is beneficial if the surface of the contact surface is smooth, in particular polished, anodized or chrome-plated. rough or structured surfaces are abbrasiv, so have an exfoliating effect, which in particular embodiments may be desired.
Erfindungsgemäß vorteilhaft ist es, wenn die Frequenz des Ultraschalls zwischen 0,05 und 2,8 MHz insbesondere 0,8 bis 1,2 MHz liegt, wobei die ausgesendete Energie nicht höher als 1000 mW/cm2 ist. Als besonders Vorteilhaft haben sich Energiedichten von 250 bis 700 mW/cm2, insbesondere 300 bis 500 mW/cm2 herausgestellt.It is advantageous according to the invention if the frequency of the ultrasound is between 0.05 and 2.8 MHz, in particular 0.8 to 1.2 MHz, the emitted energy being not higher than 1000 mW / cm 2 . Energy densities of 250 to 700 mW / cm 2 , in particular 300 to 500 mW / cm 2 , have proven to be particularly advantageous.
Bevorzugt ist die Kontaktfläche lückenlos mit dem Gehäuse des Ultraschallapplikators verbunden, so dass eine Reinigung, insbesondere eine Reinigung unter fließendem Wasser, einfach möglich ist oder zumindest spritzwassergeschützt ist. Ganz besonders bevorzugt ist es, wenn die Kontaktfläche naht- und/oder fugenlos mit dem Gehäuse verbunden ist. Erreichen kann man dies, in dem die Kontaktfläche mittels Spritzgussverfahren, insbesondere mittels Zwei- oder Mehrkomponentenspritzguss, beim Herstellungsprozess umspritzt wird.Preferably, the contact surface is completely connected to the housing of the ultrasonic applicator, so that a cleaning, in particular a cleaning under running water, is easily possible or at least splash-proof. It is particularly preferred if the contact surface is seamlessly and / or seamlessly connected to the housing. This can be achieved in that the contact surface is injection-molded by injection molding, in particular by two- or multi-component injection molding, during the production process becomes.
Vorteilhaft ist es, wenn der Ultraschallapplikator hermetisch abgeschlossen ist, das heißt ein strahlwasserdichtes Gehäuse aufweist und/oder rostfrei, insbesondere Metallfrei, auszugestalten ist, so dass z. B. auch eine Reinigung in einer Waschmaschine und/oder Geschirrspüler möglich ist.Advantageous it is when the ultrasound applicator hermetically sealed is, that is a jet-waterproof housing and / or stainless, in particular metal-free, to design is, so that z. As well as a cleaning in a washing machine and / or Dishwasher is possible.
Für Anwendungen im Gesichtsbereich haben sich Kontaktflächen mit einem Durchmesser von 15 bis 50 mm, insbesondere 25 bis 35 mm als vorteilhaft erwiesen. Für Anwendungen am Körper, z. B. Oberschenkel und Gesäß, haben sich Kontaktflächen mit einem Durchmesser von 30 bis 90 mm, insbesondere 50 bis 90 mm als vorteilhaft erwiesen.For Applications in the facial area have contact surfaces with a diameter of 15 to 50 mm, in particular 25 to 35 mm proved to be advantageous. For applications on the body, z. B. thighs and buttocks, have contact surfaces with a diameter of 30 to 90 mm, in particular 50 to 90 mm as proved advantageous.
Um die Gleitfähigkeit zu verbessern, hat es sich als vorteilhaft erwiesen, die Kontaktfläche ohne scharfe Kanten zu gestalten, z. B. gefasst oder abgerundet bzw. konkav.Around To improve the lubricity, it has proved to be beneficial proven to design the contact surface without sharp edges, z. B. taken or rounded or concave.
Auch bringt die Austauschbarkeit der Kontaktfläche den Vorteil, dass je nach Anwendungsbereich Kontaktflächen unterschiedlicher Größe oder Form mit derselben Ultraschallerreger verwendet werden können.Also brings the interchangeability of the contact surface the advantage that depending on the application area contact surfaces of different Size or shape with the same ultrasound can be used.
In diesem Fall muss die Verbindung von Kontaktfläche und Ultraschallerreger so gestaltet werden, dass die Ultraschallschwingungen auf die Kontaktfläche übertragen werden. Vorteilhaft ist es wenn die Kontraktfläche mit dem Ultraschallerreger verrastet ist. Denkbar ist auch eine Verbindung die in Form eines Klettverschlusses oder reversiblen Verklebung ausgebildet ist.In In this case, the connection must be from contact surface and ultrasound be designed so that the ultrasonic vibrations transmitted to the contact surface become. It is advantageous if the contract area with the ultrasonic exciter is locked. Also conceivable is a connection in the form of a Velcro or reversible bonding is trained.
Aus ergonomischen Gründen, insbesondere der Gewährleistung einer guten Erreichbarkeit aller Körperstellen und der Möglichkeit einer einhändigen Benutzung bei ständigem planem Aufliegen der Kontaktfläche auf der Haut, hat sich eine Abwinklung der Kontaktfläche zur Grifffläche im Winkel von 85 bis 165° als vorteilhaft erwiesen.Out ergonomic reasons, especially the warranty a good accessibility of all parts of the body and the Possibility of one-handed use with constant Plane resting the contact surface on the skin, has become an angling of the contact surface to the gripping surface at an angle of 85 to 165 ° proved to be advantageous.
Bei einer weiteren Ausführungsform der Erfindung ist es möglich die kosmetische Zubereitung direkt an der Kontaktfläche aus dem Applikator auszugeben. Dazu weist der Applikator ein Behältnis (Reservoir) für die Zubereitung auf, wobei die Ausgabe der Zubereitung aus dem Behälter durch ein Leitungssystem, welches neben der Kontaktfläche mündet möglich ist. Vorteilhaft wird die Dosierung der kosmetischen Zubereitung mittels Drucks (z. B. Behältnis wird mit Gas- oder Federdruck beaufschlagt und die austretende Menge überein manuell oder automatisch betätigtes Ventil gesteuert) oder Saugens (z. B. manuell oder automatisch betriebene Pumpe, insbesondere Membranpumpe) erfolgt.at Another embodiment of the invention makes it possible the cosmetic preparation directly at the contact surface from the applicator. For this purpose, the applicator has a container (Reservoir) for the preparation, the output the preparation from the container through a conduit system, which opens next to the contact surface possible is. Advantageously, the dosage of the cosmetic preparation by means of pressure (eg container is filled with gas or spring pressure charged and emanating amount manually or automatically operated valve) or suction (eg manually or automatically operated pump, in particular diaphragm pump) he follows.
Bevorzugt wird der Applikator so gestaltet, dass das Reservoir nachfüllbar oder auswechselbar ist.Prefers The applicator is designed so that the reservoir refillable or interchangeable.
In
den
ZITATE ENTHALTEN IN DER BESCHREIBUNGQUOTES INCLUDE IN THE DESCRIPTION
Diese Liste der vom Anmelder aufgeführten Dokumente wurde automatisiert erzeugt und ist ausschließlich zur besseren Information des Lesers aufgenommen. Die Liste ist nicht Bestandteil der deutschen Patent- bzw. Gebrauchsmusteranmeldung. Das DPMA übernimmt keinerlei Haftung für etwaige Fehler oder Auslassungen.This list The documents listed by the applicant have been automated generated and is solely for better information recorded by the reader. The list is not part of the German Patent or utility model application. The DPMA takes over no liability for any errors or omissions.
Zitierte PatentliteraturCited patent literature
- - WO 2005/004972 [0008] WO 2005/004972 [0008]
Claims (16)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102008009461A DE102008009461A1 (en) | 2008-02-15 | 2008-02-15 | Reducing the wrinkle, comprises applying a cosmetic preparation on the skin to be treated and subsequently working up by means of an ultrasonic applicator |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102008009461A DE102008009461A1 (en) | 2008-02-15 | 2008-02-15 | Reducing the wrinkle, comprises applying a cosmetic preparation on the skin to be treated and subsequently working up by means of an ultrasonic applicator |
Publications (1)
Publication Number | Publication Date |
---|---|
DE102008009461A1 true DE102008009461A1 (en) | 2009-08-20 |
Family
ID=40874026
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE102008009461A Withdrawn DE102008009461A1 (en) | 2008-02-15 | 2008-02-15 | Reducing the wrinkle, comprises applying a cosmetic preparation on the skin to be treated and subsequently working up by means of an ultrasonic applicator |
Country Status (1)
Country | Link |
---|---|
DE (1) | DE102008009461A1 (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9649376B2 (en) | 2010-09-27 | 2017-05-16 | Siwa Corporation | Selective removal of age-modified cells for treatment of atherosclerosis |
US9993535B2 (en) | 2014-12-18 | 2018-06-12 | Siwa Corporation | Method and composition for treating sarcopenia |
US10358502B2 (en) | 2014-12-18 | 2019-07-23 | Siwa Corporation | Product and method for treating sarcopenia |
US10584180B2 (en) | 2014-09-19 | 2020-03-10 | Siwa Corporation | Anti-AGE antibodies for treating inflammation and auto-immune disorders |
US10858449B1 (en) | 2017-01-06 | 2020-12-08 | Siwa Corporation | Methods and compositions for treating osteoarthritis |
US10919957B2 (en) | 2017-04-13 | 2021-02-16 | Siwa Corporation | Humanized monoclonal advanced glycation end-product antibody |
US10925937B1 (en) | 2017-01-06 | 2021-02-23 | Siwa Corporation | Vaccines for use in treating juvenile disorders associated with inflammation |
US10961321B1 (en) | 2017-01-06 | 2021-03-30 | Siwa Corporation | Methods and compositions for treating pain associated with inflammation |
US10960234B2 (en) | 2010-11-22 | 2021-03-30 | Siwa Corporation | Selective removal of cells having accumulated agents |
US10995151B1 (en) | 2017-01-06 | 2021-05-04 | Siwa Corporation | Methods and compositions for treating disease-related cachexia |
US11213585B2 (en) | 2016-06-23 | 2022-01-04 | Siwa Corporation | Vaccines for use in treating various diseases and disorders |
US11261241B2 (en) | 2008-05-23 | 2022-03-01 | Siwa Corporation | Methods, compositions and apparatuses for facilitating regeneration |
US11518801B1 (en) | 2017-12-22 | 2022-12-06 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
US11833202B2 (en) | 2016-02-19 | 2023-12-05 | Siwa Corporation | Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (AGE) |
US11958900B2 (en) | 2016-04-15 | 2024-04-16 | Siwa Corporation | Anti-age antibodies for treating neurodegenerative disorders |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005004972A1 (en) | 2003-06-13 | 2005-01-20 | The Procter & Gamble Company | Sonophoresis skin care device |
-
2008
- 2008-02-15 DE DE102008009461A patent/DE102008009461A1/en not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005004972A1 (en) | 2003-06-13 | 2005-01-20 | The Procter & Gamble Company | Sonophoresis skin care device |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11261241B2 (en) | 2008-05-23 | 2022-03-01 | Siwa Corporation | Methods, compositions and apparatuses for facilitating regeneration |
US9649376B2 (en) | 2010-09-27 | 2017-05-16 | Siwa Corporation | Selective removal of age-modified cells for treatment of atherosclerosis |
US10226531B2 (en) | 2010-09-27 | 2019-03-12 | Siwa Corporation | Selective removal of age-modified cells for treatment of atherosclerosis |
US10960234B2 (en) | 2010-11-22 | 2021-03-30 | Siwa Corporation | Selective removal of cells having accumulated agents |
US10584180B2 (en) | 2014-09-19 | 2020-03-10 | Siwa Corporation | Anti-AGE antibodies for treating inflammation and auto-immune disorders |
US9993535B2 (en) | 2014-12-18 | 2018-06-12 | Siwa Corporation | Method and composition for treating sarcopenia |
US11872269B2 (en) | 2014-12-18 | 2024-01-16 | Siwa Corporation | Method and composition for treating sarcopenia |
US11873345B2 (en) | 2014-12-18 | 2024-01-16 | Siwa Corporation | Product and method for treating sarcopenia |
US10358502B2 (en) | 2014-12-18 | 2019-07-23 | Siwa Corporation | Product and method for treating sarcopenia |
US11833202B2 (en) | 2016-02-19 | 2023-12-05 | Siwa Corporation | Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (AGE) |
US11958900B2 (en) | 2016-04-15 | 2024-04-16 | Siwa Corporation | Anti-age antibodies for treating neurodegenerative disorders |
US11213585B2 (en) | 2016-06-23 | 2022-01-04 | Siwa Corporation | Vaccines for use in treating various diseases and disorders |
US10961321B1 (en) | 2017-01-06 | 2021-03-30 | Siwa Corporation | Methods and compositions for treating pain associated with inflammation |
US10995151B1 (en) | 2017-01-06 | 2021-05-04 | Siwa Corporation | Methods and compositions for treating disease-related cachexia |
US10858449B1 (en) | 2017-01-06 | 2020-12-08 | Siwa Corporation | Methods and compositions for treating osteoarthritis |
US10925937B1 (en) | 2017-01-06 | 2021-02-23 | Siwa Corporation | Vaccines for use in treating juvenile disorders associated with inflammation |
US11542324B2 (en) | 2017-04-13 | 2023-01-03 | Siwa Corporation | Humanized monoclonal advanced glycation end-product antibody |
US10919957B2 (en) | 2017-04-13 | 2021-02-16 | Siwa Corporation | Humanized monoclonal advanced glycation end-product antibody |
US11518801B1 (en) | 2017-12-22 | 2022-12-06 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE102008009461A1 (en) | Reducing the wrinkle, comprises applying a cosmetic preparation on the skin to be treated and subsequently working up by means of an ultrasonic applicator | |
JP2021151531A (en) | Devices and methods for enhancing topical application of benefit agent | |
KR101127399B1 (en) | Treatment of skin using a benefit agent and an apparatus | |
DE112008003564T5 (en) | combination therapy | |
AU2016222343A1 (en) | Compositions and methods for treating blackheads | |
WO2014155111A1 (en) | Skincare compositions | |
WO2008098648A1 (en) | Method for reducing the signs of skin aging | |
JP2007159950A (en) | Cosmetic operation method | |
DE102008009472A1 (en) | Increasing skin moistness, comprises applying a cosmetic preparation on the skin to be treated and subsequently incorporating into the skin to be moistened with the help of an ultrasonic applicator | |
KR100901340B1 (en) | Cosmetic composition for anti-stretch mark effect on the skin containing dipalmitoyl hydroxyproline | |
DE102008009469A1 (en) | Method for skin tightening comprises treating the skin by applying a cosmetic preparation and subsequently incorporating into the skin to be tightened with the help of an ultrasonic applicator | |
EP1281394B1 (en) | Processes for cosmetics | |
DE102008009468A1 (en) | Method for increasing blood flow and oxygen supply of the skin comprises treating the skin by applying a cosmetic preparation and subsequently incorporating into the skin to be treated with the help of an ultrasonic applicator | |
DE102008009470A1 (en) | Preserving and protecting the physiological skin equilibrium and/or an activation of the skin regeneration, comprises applying a cosmetic preparation on the skin and incorporating into the skin with the help of an ultrasonic applicator | |
DE102008009471A1 (en) | Skin brightening and/or depigmentation of the skin, comprises applying a cosmetic preparation on the skin and subsequently incorporating into the skin with the help of an ultrasonic applicator | |
DE102007007615A1 (en) | Skin moisturizing procedure | |
RU2176536C1 (en) | Method for treating acne disease | |
RU2245131C1 (en) | Method for correcting cosmetic skin defects | |
Thamizharasan et al. | Cosmetic Devices | |
DE102013012380A1 (en) | Preparation for a skin treatment | |
EP1550436A1 (en) | Cosmetic article having improved penetration of active agents by simultaneous use of an abrasive devise | |
JP2006514047A (en) | Promotion of skin cell regeneration by water-soluble vitamin E | |
KR20180080944A (en) | Cosmetic composition containing gelcoher herbal filling powder | |
DE202011100483U1 (en) | Application system for care products with sponge applicator |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8139 | Disposal/non-payment of the annual fee |